panoramaProteomicsJenny HallqvistHomo Sapienshttps://panoramaweb.org/AD_Urine_Proteomics.urlj.hallqvist@ucl.ac.ukGreat Ormond Street Institute of Child Health, University College LondonPanoramaPublicAs disease-modifying therapies are now available for Alzheimer's disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput screening tool for diagnosing AD. We collected urine from a discovery cohort (n = 11) of well-characterised individuals with AD (n = 6) and their asymptomatic, CSF biomarker-negative study partners (n = 5) and used untargeted proteomics for biomarker discovery. Protein biomarkers identified were taken forward to develop a high-throughput, multiplexed and targeted proteomic assay which was tested on an independent cohort (n = 21). The panel of proteins identified are known to be involved in AD pathogenesis. In comparing AD and controls, a panel of proteins including MIEN1, TNFB, VCAM1, REG1B and ABCA7 had a classification accuracy of 86%. These proteins have been previously implicated in AD pathogenesis. This suggests that urine-targeted mass spectrometry has potential utility as a diagnostic screening tool in AD.A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer's Disease Diagnosis Using Targeted Proteomics and Machine Learning.Hällqvist Jenny J, Pinto Rui C RC, Heywood Wendy E WE, Cordey Jonjo J, Foulkes Alexander J M AJM, Slattery Catherine F CF, Leckey Claire A CA, Murphy Eimear C EC, Zetterberg Henrik H, Schott Jonathan M JM, Mills Kevin K, Paterson Ross W RWfalseA multiplexed urinary biomarker panel has potential for Alzheimer’s Disease Diagnosis using targeted proteomics and machine learningAs disease-modifying therapies are now available for Alzheimer’s disease (AD), accessible, accurate and affordable biomarkers to support diagnosis are urgently needed. We sought to develop a mass spectrometry-based urine test as a high-throughput screening tool for diagnosing AD. We collected urine from a discovery cohort (n=11) of well characterised individuals with AD (n=6) and their asymptomatic, CSF biomarker negative study partners (n=5) and used untargeted proteomics for biomarker discovery. Protein biomarkers identified were taken forward to develop a high-throughput, multiplexed and targeted proteomic assay which was tested on an independent cohort (n=21). The panel of proteins identified are known to be involved in AD pathogenesis. In comparing AD and controls, a panel of proteins including MIEN1, TNFB, VCAM1, REG1B and ABCA7 had a classification accuracy of 86%. These proteins have been previously implicated in AD pathogenesis. This suggests that urine targeted mass spectrometry has potential utility as a diagnostic screening tool in AD.Mon May 04 00:00:00 BST 2026PXD044751960637762058